Literature DB >> 31335328

Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution.

Abdel Nasser Hosein1,2,3, Huocong Huang1, Zhaoning Wang4, Kamalpreet Parmar5, Wenting Du1, Jonathan Huang3, Anirban Maitra3,6, Eric Olson4, Udit Verma2, Rolf A Brekken1,7,8.   

Abstract

Pancreatic ductal adenocarcinoma (PDA) is a major cause of cancer-related death with limited therapeutic options available. This highlights the need for improved understanding of the biology of PDA progression, a highly complex and dynamic process featuring changes in cancer cells and stromal cells. A comprehensive characterization of PDA cancer cell and stromal cell heterogeneity during disease progression is lacking. In this study, we aimed to profile cell populations and understand their phenotypic changes during PDA progression. To that end, we employed single-cell RNA sequencing technology to agnostically profile cell heterogeneity during different stages of PDA progression in genetically engineered mouse models. Our data indicate that an epithelial-to-mesenchymal transition of cancer cells accompanies tumor progression in addition to distinct populations of macrophages with increasing inflammatory features. We also noted the existence of three distinct molecular subtypes of fibroblasts in the normal mouse pancreas, which ultimately gave rise to two distinct populations of fibroblasts in advanced PDA, supporting recent reports on intratumoral fibroblast heterogeneity. Our data also suggest that cancer cells and fibroblasts may be dynamically regulated by epigenetic mechanisms. This study systematically describes the landscape of cellular heterogeneity during the progression of PDA and has the potential to act as a resource in the development of therapeutic strategies against specific cell populations of the disease.

Entities:  

Keywords:  Cancer; Gastroenterology; Oncology

Mesh:

Year:  2019        PMID: 31335328      PMCID: PMC6777805          DOI: 10.1172/jci.insight.129212

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  52 in total

1.  Counting absolute numbers of molecules using unique molecular identifiers.

Authors:  Teemu Kivioja; Anna Vähärautio; Kasper Karlsson; Martin Bonke; Martin Enge; Sten Linnarsson; Jussi Taipale
Journal:  Nat Methods       Date:  2011-11-20       Impact factor: 28.547

2.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

3.  Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.

Authors:  Dominic E Sanford; Brian A Belt; Roheena Z Panni; Allese Mayer; Anjali D Deshpande; Danielle Carpenter; Jonathan B Mitchem; Stacey M Plambeck-Suess; Lori A Worley; Brian D Goetz; Andrea Wang-Gillam; Timothy J Eberlein; David G Denardo; Simon Peter Goedegebuure; David C Linehan
Journal:  Clin Cancer Res       Date:  2013-05-07       Impact factor: 12.531

4.  Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis.

Authors:  Katherine T Ostapoff; Bercin Kutluk Cenik; Miao Wang; Risheng Ye; Xiaohong Xu; Desiree Nugent; Moriah M Hagopian; Mary Topalovski; Lee B Rivera; Kyla D Carroll; Rolf A Brekken
Journal:  Cancer Res       Date:  2014-07-24       Impact factor: 12.701

5.  Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells.

Authors:  Motoko Izumiya; Ayano Kabashima; Hajime Higuchi; Toru Igarashi; Gen Sakai; Hideko Iizuka; Shoko Nakamura; Masayuki Adachi; Yasuo Hamamoto; Shinsuke Funakoshi; Hiromasa Takaishi; Toshifumi Hibi
Journal:  Anticancer Res       Date:  2012-09       Impact factor: 2.480

6.  Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.

Authors:  Giannicola Genovese; Alessandro Carugo; James Tepper; Frederick Scott Robinson; Liren Li; Maria Svelto; Luigi Nezi; Denise Corti; Rosalba Minelli; Piergiorgio Pettazzoni; Tony Gutschner; Chia-Chin Wu; Sahil Seth; Kadir Caner Akdemir; Elisabetta Leo; Samirkumar Amin; Marco Dal Molin; Haoqiang Ying; Lawrence N Kwong; Simona Colla; Koichi Takahashi; Papia Ghosh; Virginia Giuliani; Florian Muller; Prasenjit Dey; Shan Jiang; Jill Garvey; Chang-Gong Liu; Jianhua Zhang; Timothy P Heffernan; Carlo Toniatti; Jason B Fleming; Michael G Goggins; Laura D Wood; Alessandro Sgambato; Abbas Agaimy; Anirban Maitra; Charles W M Roberts; Huamin Wang; Andrea Viale; Ronald A DePinho; Giulio F Draetta; Lynda Chin
Journal:  Nature       Date:  2017-02-08       Impact factor: 49.962

7.  Cancer-associated stromal fibroblasts promote pancreatic tumor progression.

Authors:  Rosa F Hwang; Todd Moore; Thiruvengadam Arumugam; Vijaya Ramachandran; Keith D Amos; Armando Rivera; Baoan Ji; Douglas B Evans; Craig D Logsdon
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

8.  Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors.

Authors:  Magdolna Djurec; Osvaldo Graña; Albert Lee; Kevin Troulé; Elisa Espinet; Lavinia Cabras; Carolina Navas; María Teresa Blasco; Laura Martín-Díaz; Miranda Burdiel; Jing Li; Zhaoqi Liu; Mireia Vallespinós; Francisco Sanchez-Bueno; Martin R Sprick; Andreas Trumpp; Bruno Sainz; Fátima Al-Shahrour; Raul Rabadan; Carmen Guerra; Mariano Barbacid
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-19       Impact factor: 11.205

9.  Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous.

Authors:  Wei-Jen Chung; Anneleen Daemen; Jason H Cheng; Jason E Long; Jonathan E Cooper; Bu-Er Wang; Christopher Tran; Mallika Singh; Florian Gnad; Zora Modrusan; Oded Foreman; Melissa R Junttila
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-04       Impact factor: 11.205

10.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Authors:  Christine Feig; James O Jones; Matthew Kraman; Richard J B Wells; Andrew Deonarine; Derek S Chan; Claire M Connell; Edward W Roberts; Qi Zhao; Otavia L Caballero; Sarah A Teichmann; Tobias Janowitz; Duncan I Jodrell; David A Tuveson; Douglas T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

View more
  54 in total

1.  Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts.

Authors:  Mohan Bolisetty; Pasquale Laise; William F Flynn; Ela Elyada; Elise T Courtois; Richard A Burkhart; Jonathan A Teinor; Pascal Belleau; Giulia Biffi; Matthew S Lucito; Santhosh Sivajothi; Todd D Armstrong; Dannielle D Engle; Kenneth H Yu; Yuan Hao; Christopher L Wolfgang; Youngkyu Park; Jonathan Preall; Elizabeth M Jaffee; Andrea Califano; Paul Robson; David A Tuveson
Journal:  Cancer Discov       Date:  2019-06-13       Impact factor: 39.397

Review 2.  Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer.

Authors:  Huocong Huang; Rolf A Brekken
Journal:  Am J Physiol Cell Physiol       Date:  2020-05-20       Impact factor: 4.249

3.  Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.

Authors:  Abdel Nasser Hosein; Gita Dangol; Takashi Okumura; Jason Roszik; Kimal Rajapakshe; Megan Siemann; Mohamed Zaid; Bidyut Ghosh; Maria Monberg; Paola A Guerrero; Aatur Singhi; Cara L Haymaker; Hans Clevers; Lotfi Abou-Elkacem; Sonja M Woermann; Anirban Maitra
Journal:  Gastroenterology       Date:  2021-12-30       Impact factor: 22.682

Review 4.  Clinical and therapeutic relevance of cancer-associated fibroblasts.

Authors:  Yang Chen; Kathleen M McAndrews; Raghu Kalluri
Journal:  Nat Rev Clin Oncol       Date:  2021-09-06       Impact factor: 66.675

5.  AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer.

Authors:  Wenting Du; Natalie Z Phinney; Huocong Huang; Zhaoning Wang; Jill Westcott; Jason E Toombs; Yuqing Zhang; Muhammad S Beg; Thomas M Wilkie; James B Lorens; Rolf A Brekken
Journal:  Mol Cancer Res       Date:  2021-04-02       Impact factor: 5.852

6.  Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer.

Authors:  Yang Chen; Jiha Kim; Sujuan Yang; Huamin Wang; Chang-Jiun Wu; Hikaru Sugimoto; Valerie S LeBleu; Raghu Kalluri
Journal:  Cancer Cell       Date:  2021-03-04       Impact factor: 31.743

7.  A Cancer Cell Cluster Marked by LincRNA MEG3 Leads Pancreatic Ductal Adenocarcinoma Metastasis.

Authors:  Hong Pan; Huanrong Diao; Wen Zhong; Taifang Wang; Ping Wen; Chunli Wu
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

8.  Single-Cell Transcriptomics Reveals a Conserved Metaplasia Program in Pancreatic Injury.

Authors:  Zhibo Ma; Nikki K Lytle; Bob Chen; Nidhi Jyotsana; Sammy Weiser Novak; Charles J Cho; Leah Caplan; Olivia Ben-Levy; Abigail C Neininger; Dylan T Burnette; Vincent Q Trinh; Marcus C B Tan; Emilee A Patterson; Rafael Arrojo E Drigo; Rajshekhar R Giraddi; Cynthia Ramos; Anna L Means; Ichiro Matsumoto; Uri Manor; Jason C Mills; James R Goldenring; Ken S Lau; Geoffrey M Wahl; Kathleen E DelGiorno
Journal:  Gastroenterology       Date:  2021-10-23       Impact factor: 22.682

9.  Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies.

Authors:  Jaewon J Lee; Vincent Bernard; Alexander Semaan; Maria E Monberg; Jonathan Huang; Bret M Stephens; Daniel Lin; Kimal I Rajapakshe; Brian R Weston; Manoop S Bhutani; Cara L Haymaker; Chantale Bernatchez; Cullen M Taniguchi; Anirban Maitra; Paola A Guerrero
Journal:  Clin Cancer Res       Date:  2021-08-23       Impact factor: 12.531

Review 10.  Diversity and Biology of Cancer-Associated Fibroblasts.

Authors:  Giulia Biffi; David A Tuveson
Journal:  Physiol Rev       Date:  2020-05-28       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.